Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Update

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 5,761 shares, a decrease of 65.5% from the June 30th total of 16,698 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 17,142 shares, the short-interest ratio is presently 0.3 days.

Analysts Set New Price Targets

BOLT has been the topic of a number of recent research reports. Rodman & Renshaw started coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $34.67.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock traded down $0.01 during trading hours on Tuesday, reaching $3.96. The stock had a trading volume of 5,928 shares, compared to its average volume of 25,669. The firm has a market capitalization of $7.60 million, a PE ratio of -0.24 and a beta of 1.16. The firm has a 50-day simple moving average of $4.38 and a 200-day simple moving average of $4.81. Bolt Biotherapeutics has a twelve month low of $3.75 and a twelve month high of $7.20. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%.The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $1.50 million. As a group, equities analysts forecast that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new stake in Bolt Biotherapeutics in the 3rd quarter valued at approximately $89,000. Renaissance Technologies LLC grew its stake in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after purchasing an additional 26,400 shares in the last quarter. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics in the third quarter worth $85,000. Squarepoint Ops LLC increased its holdings in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the period. Finally, T3 Companies LLC acquired a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at $208,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.